Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2021-12-06 Regulatory Filings
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx wins Swedish tender for surface disinfection: ”This is a milestone
Regulatory Filings Classification · 95% confidence The document is a short announcement detailing a business development: SoftOx winning a Swedish public tender for surface disinfection products. It includes quotes from the CEO, mentions regulatory context (Biocides Regulations), and concludes with contact information and a statement that the information is 'inside information pursuant to MAR article 7, and is publicly disclosed in accordance with MAR article 17.' This structure—a brief news item about a significant event, often related to business operations or regulatory milestones, released to the public market—is characteristic of a general regulatory announcement that doesn't fit the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, SHA, CAP). Given the options, the most appropriate fallback category for a general, market-sensitive announcement that isn't a formal financial report or specific corporate action is Regulatory Filings (RNS). The document length is short (1988 chars), suggesting it is an announcement rather than a full report.
2021-12-06 English
EU-kommisjonens tolkning av Biocidregelverket åpner for at SoftOx kan gå i markedet med alle sine desinfeksjonsprodukter i EU og EØS området
Legal Proceedings Report Classification · 99% confidence The document is a short announcement (2637 characters) detailing a positive regulatory interpretation from the EU Commission regarding the Biocidal Products Regulation, which allows SoftOx to market its disinfection products in the EU/EEA. It mentions the ability to fulfill obligations with Sykehusinnkjøp (HINAS) and prepares for market entry. Crucially, it concludes by stating that the information is defined as inside information pursuant to MAR Article 7 and is published in accordance with MAR Article 7. This structure—a brief update on a significant event, often regulatory or operational, published under MAR disclosure rules—is characteristic of a general regulatory announcement rather than a comprehensive report (like 10-K or IR) or a specific financial event (like DIV or ER). Since it doesn't fit neatly into the other specific categories (like DIRS, MANG, or CAP), the most appropriate fallback category for a general regulatory disclosure is RNS (Regulatory Filings). The 'Menu vs Meal' rule suggests that since this is an announcement about a regulatory development rather than the full report itself, RNS is the correct classification.
2021-12-01 Norwegian
The EU Commission's interpretation of the Biocidal Regulations can allow SoftOx to enter the market with all its disinfectant products in the EU and EEA area
Regulatory Filings Classification · 100% confidence The document discusses a significant regulatory development concerning the EU Commission's interpretation of Biocidal Regulations, which impacts the company's ability to sell its disinfectant products in the EU/EEA. It includes quotes from the CEO about market entry and fulfilling obligations under an agreement (HINAS). The text explicitly states, "The information included in this announcement is defined as inside information pursuant to MAR article 7, and is publicly disclosed in accordance with MAR article 17." This structure—a brief announcement conveying material, non-public information that has just been made public—is characteristic of a general regulatory disclosure or press release, rather than a comprehensive report (like 10-K or IR) or a specific financial event (like DIV or ER). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, MANG, or CAP, the most appropriate fallback category is Regulatory Filings (RNS). The document length (2753 chars) is short, suggesting it is an announcement, not the full report itself.
2021-12-01 English
SoftOx Solutions AS: Norges Forskningsråd innvilger 2,4 MNOK til utvikling av multiprodukt for forvaret
Capital/Financing Update Classification · 95% confidence The document is a short announcement detailing that the Research Council of Norway (Norges Forskningsråd) has granted approximately 2.4 MNOK to SoftOx Defense Solutions for a PhD project related to developing a multi-product for the Norwegian Armed Forces (Forsvaret). This is a specific, non-periodic corporate event announcement concerning funding/grants, which does not fit the definitions for 10-K, ER, IR, or standard capital changes. It is a specific update on financing/development support. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate category as it relates to securing funds for development, although it is a grant rather than traditional financing. Since it is a specific announcement about securing funds/grants for development, CAP is the best fit over the general 'RNS' fallback.
2021-11-22 Norwegian
SoftOx Solutions AS: The Research Council of Norway grants NOK 2.4 million for the development of a multi-product for use by the Armed Forces.
Regulatory Filings Classification · 94% confidence The document announces a specific event: a grant of NOK 2.4 million awarded to SoftOx Solutions AS's subsidiary by The Research Council of Norway for product development related to the Armed Forces. This is not a standard periodic financial report (like 10-K, IR, ER), nor is it a management change (MANG) or director dealing (DIRS). It relates to funding, development, and strategic activity. Among the provided codes, 'CAP' (Capital/Financing Update) is the closest fit as it involves receiving significant non-equity funding/grants that impact the company's resources and development trajectory. It is a specific announcement about securing funds for a project, which falls under financing activities.
2021-11-22 English
SoftOx Solutions AS Strategy and Capital Markets Day, including Q3 2021 Presentation
Report Publication Announcement Classification · 98% confidence The document text is extremely short (319 characters) and explicitly states that a presentation for the 'Strategy and Capital Markets Day, including Q3 2021 Presentation' is attached or available via a link. This structure—a brief announcement pointing to the main content—fits the definition of a Report Publication Announcement (RPA) rather than the Investor Presentation (IP) itself, adhering to the 'MENU VS MEAL' rule. The content is clearly an investor-focused presentation/update.
2021-11-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.